Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 959.92 -0.47% -4.55
REGN closed down 0.47 percent on Monday, March 18, 2024, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
NR7 Range Contraction 0.00%
Gapped Up Strength 0.00%
Pocket Pivot Bullish Swing Setup -0.47%
Inside Day Range Contraction -0.47%
20 DMA Resistance Bearish 0.09%
Fell Below 20 DMA Bearish -0.57%
Gapped Up Strength -0.57%
Crossed Above 20 DMA Bullish -1.10%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.10%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 13 hours ago
Possible NR7 about 14 hours ago
10 DMA Resistance about 19 hours ago
10 DMA Support about 19 hours ago
Rose Above Previous Day's High about 19 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Regeneron Pharmaceuticals, Inc. Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: S&P 500 Medicine Biotechnology Biopharmaceutical Nasdaq 100 Immunology Pain Clinical Development Infectious Diseases Antibodies Monoclonal Antibodies Bone Inflammation Disorders Cardiovascular Disease Clinical Research Ophthalmology Colorectal Cancer Macular Degeneration Rheumatoid Arthritis Vascular Disease Asthma Breakthrough Therapy Cholesterol Atopic Dermatitis Macular Edema Syndromes Dermatitis Lipoprotein Cartilage Angiogenesis Human Monoclonal Antibodies Immune Diseases Metastatic Colorectal Cancer Regeneron Muscle Disease Muscle Diseases

Is REGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 998.32
52 Week Low 684.805
Average Volume 439,387
200-Day Moving Average 837.43
50-Day Moving Average 950.97
20-Day Moving Average 969.98
10-Day Moving Average 966.34
Average True Range 16.69
RSI (14) 49.49
ADX 17.12
+DI 16.11
-DI 17.25
Chandelier Exit (Long, 3 ATRs) 948.25
Chandelier Exit (Short, 3 ATRs) 993.80
Upper Bollinger Bands 993.35
Lower Bollinger Band 946.60
Percent B (%b) 0.28
BandWidth 4.82
MACD Line 4.35
MACD Signal Line 7.71
MACD Histogram -3.3556
Fundamentals Value
Market Cap 103.62 Billion
Num Shares 108 Million
EPS 34.80
Price-to-Earnings (P/E) Ratio 27.58
Price-to-Sales 7.90
Price-to-Book 4.03
PEG Ratio 1.94
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 976.75
Resistance 3 (R3) 978.48 974.59 973.95
Resistance 2 (R2) 974.59 970.31 973.73 973.01
Resistance 1 (R1) 967.26 967.66 965.32 965.53 972.07
Pivot Point 963.37 963.37 962.40 962.51 963.37
Support 1 (S1) 956.04 959.09 954.10 954.31 947.77
Support 2 (S2) 952.15 956.44 951.29 946.83
Support 3 (S3) 944.82 952.15 945.90
Support 4 (S4) 943.09